RVL Pharmaceuticals plc (RVLP)

NASDAQ: RVLP · IEX Real-Time Price · USD
1.37
-0.01 (-0.72%)
At close: May 23, 2022 4:00 PM
1.36
-0.01 (-0.73%)
After-hours:May 23, 2022 7:06 PM EDT
Market Cap114.46M
Revenue (ttm)38.01M
Net Income (ttm)-62.13M
Shares Out83.55M
EPS (ttm)-0.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,446
Open1.38
Previous Close1.38
Day's Range1.37 - 1.39
52-Week Range0.98 - 4.85
Beta1.54
AnalystsBuy
Price Target5.30 (+286.9%)
Earnings DateMay 12, 2022

About RVLP

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed i...

IndustryBiotechnology
Founded2000
Employees156
Stock ExchangeNASDAQ
Ticker SymbolRVLP
Full Company Profile

Financial Performance

In 2021, RVLP's revenue was $17.50 million, a decrease of -36.96% compared to the previous year's $27.76 million. Losses were -$64.92 million, -18.43% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RVLP stock is "Buy." The 12-month stock price forecast is 5.3, which is an increase of 286.86% from the latest price.

Price Target
$5.3
(286.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

RVL Pharmaceuticals plc to Present at Upcoming Conferences

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Execut...

1 week ago - GlobeNewsWire

RVL Pharmaceuticals PLC (RVLP) Reports Q1 Loss, Tops Revenue Estimates

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 48% and 197.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021

1 week ago - GlobeNewsWire

UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"

BRIDGEWATER, N.J. , May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride oph...

2 weeks ago - PRNewsWire

RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update

Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET

2 weeks ago - GlobeNewsWire

UPNEEQ® Wins "Best in Innovation" Award from New Beauty

12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquired ...

1 month ago - PRNewsWire

RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results

-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidanc...

1 month ago - GlobeNewsWire

RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quart...

Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales

1 month ago - GlobeNewsWire

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022...

-- Conference call to be held March 30, 2022, at 4:30 p.m. ET -- -- Conference call to be held March 30, 2022, at 4:30 p.m. ET --

2 months ago - GlobeNewsWire

RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022

BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exec...

2 months ago - GlobeNewsWire

UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “...

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 mil...

4 months ago - GlobeNewsWire

Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook

Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's str...

4 months ago - Benzinga

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Pl...

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 mil...

4 months ago - GlobeNewsWire

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --

4 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...

4 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...

5 months ago - GlobeNewsWire

Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates

Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales

6 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...

6 months ago - GlobeNewsWire

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will ...

6 months ago - GlobeNewsWire

Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for

Osmotica Pharmaceuticals (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 20...

7 months ago - GlobeNewsWire

Here's why Osmotica Pharmaceuticals is down 35% on Thursday

Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to gen...

7 months ago - Invezz

Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered in...

7 months ago - GlobeNewsWire